HC Wainwright Raises Balchem (NASDAQ:BCPC) Price Target to $185.00

Balchem (NASDAQ:BCPC) had its price target lifted by HC Wainwright from $170.00 to $185.00 in a research note released on Wednesday, Benzinga reports. HC Wainwright currently has a buy rating on the basic materials company’s stock. HC Wainwright also issued estimates for Balchem’s Q1 2025 earnings at $1.04 EPS, Q2 2025 earnings at $1.08 EPS, Q3 2025 earnings at $1.12 EPS, Q4 2025 earnings at $1.16 EPS and FY2025 earnings at $4.40 EPS.

Separately, StockNews.com lowered Balchem from a buy rating to a hold rating in a research note on Monday, July 29th.

Balchem Stock Performance

BCPC opened at $171.47 on Wednesday. The firm has a market cap of $5.56 billion, a PE ratio of 47.97, a P/E/G ratio of 5.67 and a beta of 0.67. The business has a fifty day simple moving average of $160.72 and a 200-day simple moving average of $153.33. The company has a quick ratio of 1.79, a current ratio of 2.83 and a debt-to-equity ratio of 0.26. Balchem has a fifty-two week low of $110.74 and a fifty-two week high of $186.03.

Balchem (NASDAQ:BCPC) last released its quarterly earnings data on Friday, May 3rd. The basic materials company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). Balchem had a net margin of 12.52% and a return on equity of 10.94%. The firm had revenue of $239.66 million for the quarter, compared to analyst estimates of $234.12 million. As a group, equities analysts predict that Balchem will post 3.91 EPS for the current fiscal year.

Insider Transactions at Balchem

In related news, Director David B. Fischer sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 8th. The shares were sold at an average price of $152.98, for a total value of $764,900.00. Following the completion of the transaction, the director now owns 9,009 shares in the company, valued at approximately $1,378,196.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director David B. Fischer sold 5,000 shares of the company’s stock in a transaction on Wednesday, May 8th. The shares were sold at an average price of $152.98, for a total value of $764,900.00. Following the completion of the transaction, the director now directly owns 9,009 shares of the company’s stock, valued at approximately $1,378,196.82. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Michael Robert Sestrick sold 1,929 shares of the stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $154.45, for a total transaction of $297,934.05. Following the transaction, the senior vice president now owns 4,878 shares of the company’s stock, valued at $753,407.10. The disclosure for this sale can be found here. Insiders have sold 14,679 shares of company stock valued at $2,458,222 in the last three months. 1.25% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Balchem

Several hedge funds have recently bought and sold shares of BCPC. TD Asset Management Inc bought a new position in Balchem in the second quarter valued at approximately $200,000. Natixis Advisors LLC lifted its holdings in Balchem by 1.8% in the second quarter. Natixis Advisors LLC now owns 21,344 shares of the basic materials company’s stock valued at $3,286,000 after buying an additional 375 shares during the period. Van ECK Associates Corp lifted its holdings in Balchem by 0.8% in the second quarter. Van ECK Associates Corp now owns 64,829 shares of the basic materials company’s stock valued at $9,980,000 after buying an additional 485 shares during the period. Sage Rhino Capital LLC acquired a new position in Balchem in the second quarter valued at $207,000. Finally, Heritage Family Offices LLP acquired a new position in Balchem in the second quarter valued at $206,000. 87.91% of the stock is currently owned by institutional investors and hedge funds.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.